A comparison of the efficacy and safety of entecavir versus lamivudine through 240 weeks of treatment in Korean patients with HBeAg-negative chronic hepatitis B

Authors
Category Primary study
Conference65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting; 2014 Nov 7-11; Boston, MA, United States. Hepatology
Year 2014
This article has no abstract
Epistemonikos ID: aa321e98c3e6f3b3a8b3fcfe3eb0a80a2fcf589a
First added on: Nov 24, 2021